Cannabis Law Report

SEPTEMBER 13, 2021

Key objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF-?, BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. in the blood. in the blood.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

AUGUST 24, 2021

Patent protects methods of administering MYMD-1 for treating disorders associated with chronic inflammation, with a focus on fibrosis and asthma. BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc.

Pharmaceutical 75

Pharmaceutical Clinical Trials Chronic Pain CBD 75

Cannabis Law Report

SEPTEMBER 16, 2021

House lawmakers have introduced a series of drug policy-related amendments to defense legislation, including proposals to facilitate research on the benefits of psychedelics for active duty military personnel and to protect banks that service state-legal marijuana businesses.

Banking 52

Banking Clinical Trials Chronic Pain Marijuana 52

Cannabis Law Report

SEPTEMBER 6, 2021

DUBLIN–(BUSINESS WIRE)–The “Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. 12 Overview of Clinical Research Suggesting the Benefits of Medical Cannabis Across Various Indications.

Chronic Pain 66

Chronic Pain Research and Development Clinical Trials Epilepsy 66

Cannabis Law Report

JANUARY 12, 2022

. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” and three international patents that have been issued to protect therapeutic mixtures for Parkinson’s disease, chronic pain, hyperinflammation, and heart disease.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 9, 2021

DUBLIN–(BUSINESS WIRE)–The “Global Legal Cannabis Market 2021-2028” report has been added to ResearchAndMarkets.com’s offering. Global Legal Cannabis Industry: Number of Clinical Trials, By Region. Chronic Pain. The global legal cannabis market size is expected to reach USD 91.5

Recreational 73

Recreational Hemp THC Legalization 73

Veriheal

AUGUST 31, 2020

Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . About Clinton: Clinton is an undergraduate student studying business.

Research and Development 119

Research and Development Education Agriculture Patients 119

Cannabis Law Report

DECEMBER 8, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. BERWYN, Pa.–(BUSINESS Mack, Chairman and CEO of Virpax.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

MMJ Recs

APRIL 1, 2024

From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions. Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

NOVEMBER 18, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax is also preparing to commence clinical trials in Israel.”.

Pharmaceutical 40

Pharmaceutical Clinical Trials Business Chronic Pain 40

Cannabis Law Report

OCTOBER 17, 2019

Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market. The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

SpeedWeed

AUGUST 4, 2021

She moved into the television business with a major Australian network where she quickly was promoted into the position of National Travel Manager. At the age of 29, she left production and started a hospitality business which she built up into one of the best-known entertainment restaurants in Sydney. During a social trip to the U.S.

Chronic Pain 52

Chronic Pain Research and Development Medicine Supply Chain 52

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 40

Pharmaceutical Therapy Clinical Trials Chronic Pain 40

Cannabis Law Report

SEPTEMBER 14, 2021

Those insights will help bring products to market that are specifically formulated based on rigorous evidence to address need states like chronic pain, restful sleep, and general health and well-being. About Radicle Science.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

Cannabis Law Report

OCTOBER 5, 2021

MyMD to launch two simultaneous Phase 2 trials during the current quarter to study MYMD-1’s function in extending healthy lifespan and treating COVID-19-associated depression. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Media 40

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

Cannabis Law Report

JULY 4, 2021

Clinical trials across the EU have also shown CBD oils and other hemp products to have a potential range of benefits. Any CBD business looking for practice standards and a body of experts that they can phone or pose a question to should enquire about a membership. What is THC? One such online store is Dr. Hemp Me.

THC 81

THC CBD Legalization Oil 81

Cannabis Law Report

DECEMBER 29, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax is also preparing to commence clinical trials in Israel.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain CBD 40

Cannabis Law Report

SEPTEMBER 22, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD’s superior potency over CBD by factor of 8,000 times. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

The Cannigma

SEPTEMBER 21, 2021

Dubbed by SFGate “The Coach Who Rolls the Best Blunts in the NBA,” Golden State Warriors Coach Steve Kerr has admitted to using marijuana to cope with nagging back pain. But it was worth it, because I’m searching for answers on pain. Morgan Freeman says only cannabis helps reduce his fibromyalgia pain (Shutterstock).

Patients 94

Patients Research and Development Sleep Clinical Trials 94

Cannabis Law Report

JULY 4, 2019

The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Research and Development 40

Research and Development Clinical Trials Pharmaceutical Chronic Pain 40

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman Bio. Chapman has operated Chapman Pharmaceutical Consulting, Inc.,

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

NOVEMBER 10, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain.

Research and Development 40

Research and Development Chronic Pain Pharmaceutical Clinical Trials 40

The Cannigma

DECEMBER 12, 2022

Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. As such, there have been numerous clinical trials using ketamine.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

DECEMBER 28, 2021

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I BERWYN, Pa.–(BUSINESS to conduct this study in Canada.

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Expands intellectual property portfolio for lead drug candidate MYMD-1 to 12 U.S.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Chronic Pain 40

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Expands intellectual property portfolio for lead drug candidate MYMD-1 to 3 U.S.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Treatment 40

Cannabis Law Report

OCTOBER 18, 2021

DUBLIN–(BUSINESS WIRE)–The “Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic product.

Research and Development 40

Research and Development Pharmaceutical Chronic Pain Therapy 40

Cannabis Law Report

OCTOBER 1, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, today announced that Chairman and CEO Anthony P. BERWYN, Pa.–(BUSINESS

Research and Development 40

Research and Development Pharmaceutical Clinical Trials Chronic Pain 40

Cannabis Law Report

SEPTEMBER 20, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd.

Epilepsy 40

Epilepsy Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. We continue to enhance our product pipeline, and because of our unique delivery technologies we have expanded our targeted indications beyond pain to include Central Nervous System (CNS) disorders and anti-viral indications. “Our

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

JANUARY 24, 2022

DUBLIN–(BUSINESS WIRE)–The “North America Legal Cannabis Market Size, Share & Trends Analysis Report by Sources (Marijuana, Hemp), by Derivatives (CBD, THC), by End Use (Medical, Recreational), and Segment Forecasts, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. Chronic Pain.

Legalization 40

Legalization Supply Chain Chronic Pain Recreational 40

Cannabis Law Report

JULY 15, 2019

ACM takes in consideration the characteristics of medical cannabis preparations and substances, and is a simplified version of the marketing authorization required for medicinal products to some extent (for instance, no clinical trials are required). Author: João Taborda da Gama. 351 914 725 808. joao.gama@gamagloria.com.

Medicine 40

Medicine Clinical Trials Patients Access 40

The Cannigma

MARCH 12, 2021

We’re not going to get over the fact that there’s not the same sort of clinical trial and that type of evidence for cannabis and cannabis treatments in the very near future for various reasons. There’s the one drug, one target, cannabis is multiple active ingredients and acts on multiple targets in the body.

Legalization 128

Legalization Patients Education Dispensary 128

Cannabis Law Report

JUNE 9, 2022

The bill would expand patients’ access to the necessary treatment for more than 50 conditions, including cancer and post-traumatic stress disorder (PTSD), neurological diseases, and chronic pain of neuropathic origin. “ 8) Article 17 shall be worded as follows: Article 17.

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52